甘氨双唑钠联合放疗治疗原发性鼻咽癌的有效性和安全性的Meta分析

发布时间：2018-07-11 14:34

本文选题：甘氨双唑钠 + 鼻咽癌　；参考：《中国临床药理学杂志》2017年07期

【摘要】：目的系统评价甘氨双唑钠联合放疗治疗鼻咽癌的有效性和安全性。方法检索Cochrane Library、Pub Med、EMbase、相关期刊论文、维普数据库、中国生物医学文献数据库、万方数据库,截至2016年11月。纳入甘氨双唑钠联合放疗对比单纯放疗治疗鼻咽癌患者的随机对照试验(RCT),试验组予以甘氨双唑钠联合放射疗法治疗,对照组予以单纯放射疗法治疗。用Rev Man 5.0对完全缓解率和总缓解率进行Meta分析。结果共纳入18项RCT,合计1241例患者。试验组和对照组的总缓解率分别为90.37%和72.86%;完全缓解率分别为69.23%和44.60%,差异有统计学意义(P0.05)。试验组和对照组的药物不良反应发生率分别为36.36%和36.24%,差异无统计学意义(P0.05)。结论甘氨双唑钠联合放疗治疗原发性鼻咽癌的临床疗效显著优于单纯放疗,且不增加药物不良反应的发生率。
[Abstract]:Objective to systematically evaluate the efficacy and safety of sodium glycidazole combined with radiotherapy in the treatment of nasopharyngeal carcinoma. Methods Cochrane Library, Pub Med, EMbase, Chinese journal full text database, VP database, Chinese biomedical literature database, Wanfang database, as of November 2016, were included in the combination of glycine sodium biazoles combined radiotherapy to compare simple radiotherapy treatment. The randomized controlled trial (RCT) of patients with nasopharyngeal carcinoma (nasopharyngeal carcinoma) was treated with sodium glycine sodium combined with radiotherapy, and the control group was treated with simple radiation therapy. The total remission rate and total remission rate were analyzed with Rev Man 5. The results were included in 18 RCT and 1241 patients. The total remission rate of the test group and the control group was 90.37% and the control group respectively. 72.86%, the rate of complete remission was 69.23% and 44.60%, the difference was statistically significant (P0.05). The incidence of adverse drug reactions was 36.36% and 36.24% in the experimental group and the control group, respectively (P0.05). Conclusion the clinical efficacy of GN combined with radiotherapy in the treatment of primary nasopharyngeal carcinoma was significantly better than that of radiotherapy alone, without increasing drug use. The incidence of adverse reactions.
【作者单位】：首都医科大学附属北京天坛医院药学部;北京丰台区南苑社区卫生服务中心药剂科;
【分类号】：R739.63

【相似文献】